1168results about How to "High biosecurity" patented technology

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

The invention discloses an algae-controlling bioactive preparation as well as a preparation method and application thereof. The preparation method comprises the following steps: inoculating bacillus velezensis HY16 in a bioactive substance fermentation culture medium and culturing; the culture temperature is 35-40 DEG C, and the culture time is 32-48 hours. The algae-controlling bioactive preparation provided by the invention has good capability of inhibiting growth of microcystis aeruginosa, and the algae-lysing rate of the algae-controlling bioactive preparation on microcystis aeruginosa in an aquarium system can reach 97% or above. The algae-controlling bioactive preparation prepared from the bacillus velezensis HY16 fermentation active liquid is stable in property, safe, environment-friendly and simple to apply, can be used for effectively and biologically controlling and repairing an aquarium water body with microcystis aeruginosa, is remarkable in effect, and has good market application prospect and value.

The invention discloses an inflammation-targeting bionic extracellular vesicle as well as a preparation method and application thereof, and particularly relates to the field of medicines. According to the invention, a new generation of aminoglycoside antibiotic teicoplanin (Teic), which is high in albumin binding rate and weak in intracellular antibacterial effect, is loaded on neutrophil-derived extracellular vesicles (NEV) with natural drug carrying capacity and inflammatory response chemotactic capacity to prepare the drug-loaded vesicles (Teic-NEV), wherein the new generation of aminoglycoside antibiotic teicoplanin (Teic) is used for loading the neutrophil-derived extracellular vesicles (NEV). The drug-loaded extracellular vesicle Teic-NEV can be used for targeted therapy of cells and tissues infected by MRSA (Methicillin-Resistant Staphylococcus Aureus). In vitro, the Teic (at) NEV can be used for destroying MRSA mature biological membranes and killing intracellular MRSA. According to the invention, the in-vivo and in-vitro biological safety of the TeicatNEV is evaluated. Therefore, the invention provides a certain theoretical basis for the application of NEV-based drug delivery in the field of intracellular bacteria treatment, and also provides a new treatment strategy for in-vivo targeted treatment.

The invention discloses a recombinant human-derived II-type collagen, a nucleic acid molecule, a carrier, a cell, a composition and application thereof, and relates to the technical fields of genetic engineering and synthetic biology. The recombinant human-derived II-type collagen comprises a calcium ion binding domain and has an effect of promoting osteoblast proliferation, so that the recombinant human-derived II-type collagen has a good application prospect in preparation of medical instruments and compositions. The recombinant human II-type collagen provided by the invention can be expressed in a common expression system, and has the advantages of high expression quantity and no endotoxin hidden danger. Moreover, the recombinant human II-type collagen does not carry purification labels such as histidine labels and the like, and can be purified through a molecular sieve, so that the target protein can be directly obtained finally, and the purification labels such as the histidine labels and the like do not need to be additionally cut off. The production method of the recombinant human-derived II-type collagen is suitable for industrial large-scale production, and the prepared product does not have an animal-derived infection source, so that the biological safety is higher.

The invention provides a recombinant collagen ionic liquid composition as well as a preparation method and application thereof, and relates to the technical field of cosmetics. The recombinant collagen ionic liquid composition provided by the invention is prepared from the following components in parts by mass: 19.8 to 79.99 parts of lysine citric acid ionic liquid, 20 to 80 parts of glycerol and 0.01 to 0.2 part of recombinant collagen, the lysine citric acid ionic liquid is mainly composed of lysine and citric acid, and the molar ratio of the lysine to the citric acid is (4-1): (2-1). The recombinant collagen ionic liquid composition is good in solubility, high in transdermal efficiency, small in irritation, short in preparation period, simple in process and capable of being continuously produced.

The invention belongs to the technical field of medical materials, discloses hyaluronic acid modified phosphorus-doped double-copper monatomic nano-enzyme (Cu2 / PNC at HA) and a preparation method and application thereof, and aims to solve the problems of low catalytic efficiency and poor selectivity of nano-enzyme. The preparation method comprises the following steps: firstly synthesizing a ZIF-8 carrier, then coating double copper ions and poly (cyclotriphosphoryl-4 ', 4'-diaminodiphenyl ether) (PZM) on the surface of the ZIF-8 through polymerization, and further performing pyrolysis to obtain the Cu2 / PNC nano-enzyme. The catalytic efficiency of the Cu2 / PNC nano-enzyme is remarkably improved through the phosphorus doping effect and double copper single atoms. The hyaluronic acid is adopted to coat the Cu2 / PNC nano-enzyme, so that the biocompatibility is improved, the anti-tumor activity is remarkably improved, the application of the Cu2 / PNC nano-enzyme in the field of biomedicine is expanded, and the huge potential in the aspect of tumor catalytic treatment is shown.

The invention discloses a tetrapeptide LILP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tetrapeptide LILP is Leuu-Ile-Leu-Pro, and the amino acid sequence of the tetrapeptide LILP is shown in the specification. The invention discloses that the tetrapeptide LILP has uric acid reducing activity for the first time, and uric acid generation can be reduced by reducing the activity of xanthine oxidase in the liver; uric acid discharge can be increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of health-care foods for assisting in reducing the level of uric acid, and has a good application prospect.

The invention discloses a bacteria surface modification method based on atom transfer radical polymerization reaction mediation, obtained bacteria and application. The modification method comprises the following steps: carrying out acryloylation on the surfaces of the bacteria by using N-hydroxysuccinimide acrylate, and introducing double bonds on the surfaces of the bacteria to obtain acryloylated bacteria; the method comprises the following steps: by taking acrylamide, N-(3-aminopropyl) methacrylamide hydrochloride and N, N '-methylene bisacrylamide as monomers, carrying out polymerization reaction on the surfaces of acrylated bacteria in the presence of an initiator and a catalyst; the mass ratio of the acrylamide to the N-(3-aminopropyl) methacrylamide hydrochloride to the N, N '-methylene bisacrylamide is (11.9 to 17.5) to (0.125 to 1) to (0.1 to 0.5). According to the method, bacteria can be camouflaged to reduce immunogenicity and pathogenicity of the bacteria, the safety of bacteria treatment is improved under the condition that the viability and multiplication capacity of the bacteria are not affected, the resistance of the bacteria to environmental threats is enhanced, and the bacteria are endowed with no exogenous functions.

The invention discloses a polymer drug-loaded particle for targeted adhesion to an intestinal inflammation area and a preparation method and application thereof.The method includes the steps that degradable polymer drug-loaded particles are subjected to surface modification through polycations and then added into a monomer solution of an adhesion layer, particle surface in-situ polymerization is initiated through ultraviolet irradiation, and a PAN adhesion layer is formed; the adhesion layer modified polymer drug-loaded particles are obtained. Wherein the polycation is used as a middle layer, so that the PAN adhesion layer can be successfully modified. Carboxyl in the adhesion layer enables the particles to present negative charges, meanwhile, succinimide ester can react with amino naturally existing on the surface of inflammatory intestinal tissue to generate an amide covalent bond, and finally targeted adhesion of the intestinal inflammation part is achieved. According to the adhesion strategy, the PAN can be effectively applied to the micro-nano-scale drug-loaded particles so as to enhance the adhesion of the micro-nano-scale drug-loaded particles in an intestinal tract damaged area, and a brand new thought is provided for treating inflammatory intestinal tracts.

The invention discloses a tripeptide LAF with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LAF is Leu-Ala-Phe (Leu-Ala-Phe). The tripeptide LAF disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides an active substance for reducing uric acid through multi-target action, and the active substance can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of foods for assisting in reducing the uric acid level, and has a good application prospect.

The invention provides a tumor cell exosome, an anti-tumor immune drug delivery system and a preparation method and application of the anti-tumor immune drug delivery system, the tumor cell exosome is derived from starved and stimulated tumor cells, the tumor cell exosome is coated with nano drug particles for delivery, and the exosome has the effects of enhancing immune cell infiltration and remodeling an immune microenvironment; due to the homing effect of the exosome, the medicine and the exosome are more easily accumulated in the tumor, and the targeting property is improved; due to coating and camouflage of the biological membrane of the exosome membrane, the exosome membrane is prevented from being recognized, attacked and removed by an organism, and the biological safety is improved, so that the exosome and the nano-drug act on the tumor together to achieve a synergistic effect.

The invention discloses a preparation method of a zinc-dihydromyricetin nano-enzyme and application of the zinc-dihydromyricetin nano-enzyme in preparation of drugs for promoting healing of diabetic wounds, and the zinc-dihydromyricetin metal polyphenol nano-enzyme (Zn-DHM) is obtained by coordinating a metal element zinc (Zn) and a natural product dihydromyricetin (DHM) through a one-step method by taking PVP as a surfactant. The Zn-DHM nano-enzyme prepared by the invention has antioxidant property and cell proliferation and migration promoting ability, and can maintain metabolism and immune homeostasis of diabetic wounds, so that the Zn-DHM nano-enzyme can accelerate early healing of the diabetic wounds.

The invention discloses a preparation method and application of a manganese-based amino acid coordination polymer, and belongs to the technical field of nano-enzymes and nano-drugs. Divalent manganese salt, histidine and other amino acids are subjected to a co-precipitation reaction to prepare the manganese-based amino acid coordination polymer, and the polymer is of a nanoparticle structure, small in size and high in stability, has enzyme-like activity, catalyzes hydrogen peroxide to generate high-toxicity hydroxyl free radicals and is used for specifically killing tumor cells. The catalyst has the capability of catalytically generating singlet oxygen in the presence of hydrogen peroxide. Meanwhile, the manganese-based amino acid complex has glutathione oxidase-like activity, consumes glutathione to overcome the resistance of tumors to oxidative stress, improves the chemical kinetic curative effect, and has anti-tumor application potential.

The present invention relates to a molecular imaging probe for tumor diagnosis, and provides a sugar nucleic acid molecular imaging probe, the probe comprises a DNA aptamer sequence and more than one glycosyl nucleoside module, and is labeled by radionuclide, the DNA aptamer sequence can specifically target tumor cells after functional folding; the glycosyl nucleoside module is a glycosyl modified nucleoside derivative, is accurately modified at the 5'end or / and the 3 'end of the aptamer through DNA solid-phase synthesis, has the imaging characteristics of biological safety, high sensitivity and high resolution, and has an excellent diagnosis effect on part of cancers which are difficult to diagnose by a traditional method. The invention also provides a preparation method and a use method of the sugar nucleic acid molecular imaging probe, so that sugar modification of the aptamer is convenient, rapid, accurate, controllable and modularized, and the sugar nucleic acid molecular imaging probe has huge clinical application potential and transformation value in cancer diagnosis.

The invention discloses a metarhizium aureoviride strain YEC and application of the metarhizium aureoviride strain YEC in prevention and treatment of teak camel moths. The Metarhizium anisoviride YEC provided by the invention is separated from soil in Guangdong province, can infect mangrove forest pests, namely teak camel moths, and can have relatively high fatality rate and stiff insect rate on the teak camel moths within a short time. The metarhizium aureoviride strain YEC is a biological control strain with potential development and application value in control of mangrove forest pests.

The invention discloses nanoparticles for a contrast agent as well as a preparation method and application of the nanoparticles, and relates to the technical field of nano composite materials. According to the nanoparticle for the contrast agent, a shell layer comprises polydopamine and albumin which are connected through a covalent bond, a core structure comprises a complex formed by metal ions and polyphenol, and the metal ions in the core structure and the polydopamine in the shell layer also have a coordination effect. Due to the fact that all the components are tightly connected, the rotation time of the nano-particles is prolonged, the T1 relaxation rate of the nano-particles is greatly increased, meanwhile, due to introduction of polydopamine, release of metal ions in a human body is avoided, the biological safety of the nano-particles is improved, albumin in the nano-particles can further improve the biocompatibility of the particles, and the nano-particles can be used for preparing the nano-particles. Therefore, the nanoparticles provided by the invention also have wide application prospects in the fields of fluorescence imaging and targeted drug delivery.

The invention relates to a targeted drug delivery carrier based on mesoporous polydopamine nanoparticles and application thereof.The targeted drug delivery carrier is galactose modified mesoporous dopamine coordinated with manganese ions, lysine is adopted in the carrier synthesis step to provide an alkaline environment needed by dopamine polymerization, the polymerization process is simplified, and the drug delivery efficiency is improved. Meanwhile, lysine can be introduced into the mesoporous polydopamine; and the drug loading capacity of the carrier is improved. The carrier gathers multifunctionality of drug delivery, tumor imaging and treatment, provides a comprehensive new method for tumor treatment, and enhances individuation and precision of treatment.

The invention belongs to the technical field of transcranial magnetic stimulation medical treatment. The problems that in an existing transcranial magnetic stimulation technology, the focusing performance of a deep specific brain area is not high, positioning is not accurate, and full-path superficial layer tissue is strongly stimulated are solved. According to the deep transcranial magnetic stimulation positioning navigation system based on time interference, based on the time interference principle, stimulation currents with different frequencies are applied to two sets of transmitting coils, low-frequency envelope waves are overlaid in the skull, and therefore the current magnitude is reduced, and the focusing degree is improved. Data support is provided for accurate positioning of the head posture of a patient based on a depth camera, and a multi-degree-of-freedom coil capable of generating an omni-directional magnetic field in space is provided. By reasonably adjusting the amplitude of the current introduced into the coil, the magnetic field can automatically move to the stimulation point of the head of the patient for treatment, the stimulation target is changed by adjusting the electrical parameters, and the low-frequency envelope magnetic field is obtained by modulation at the stimulation target, so that the target neurons are magnetically stimulated.

Compared with a porous microsphere in the prior art, the polymer material microsphere with the closed hollow structure is provided with the closed hollow structure or a gas chamber, the surface of the microsphere is smooth on the whole, and acute inflammatory reaction can be avoided. By adopting the microspheres prepared by the invention, the total material implantation amount can be reduced when the same regenerative stimulation point is implanted; and the preparation process is simple, and large-scale production is facilitated.

The invention relates to a PPR antibacterial pipeline and a preparation method thereof, and belongs to the technical field of pipeline processing. The sea-buckthorn extract is used as an auxiliary medium, green synthesis of the silver nanoparticles can be promoted, use of traditional toxic reducing agents and stabilizing agents is avoided, natural active ingredients contained in the sea-buckthorn extract and the silver nanoparticles generate a synergistic effect, the antibacterial efficiency is remarkably enhanced, and the dosage and biotoxicity of the silver nanoparticles are reduced. Meanwhile, the nano silicon dioxide is added, so that the coating can be kept stable in a high-temperature environment. The carboxymethyl chitosan endows the pipeline with excellent antibacterial performance, and forms a synergistic effect with the silver nanoparticles, so that the antibacterial ability of the pipeline is further enhanced. Through the modification of the silane coupling agent KH560, the interface bonding force between the nano silicon dioxide and carboxymethyl chitosan and the interface bonding force between the nano silicon dioxide and the main component PPR of the pipeline are enhanced, so that the reinforcing agent can be more uniformly and stably dispersed in a PPR matrix, and the overall performance of the pipeline is improved.

The invention discloses a boron manganese tannate nanoparticle as well as a synthesis method and application thereof. The synthesis method of the tannic acid boron manganese nanoparticles comprises the following steps: sequentially dropwise adding a bivalent manganese salt solution, a boric acid solution, a polyethylene glycol solution and a bovine serum albumin solution into pure water under water bath ultrasonic or magnetic stirring to obtain an assembly stock solution, and adding a tannic acid solution into the assembly stock solution to initiate assembly; and continuously carrying out water-bath ultrasonic treatment or magnetic stirring for a period of time, and then carrying out ultrafiltration to remove free drug molecules, so as to obtain the boron manganese tannate nanoparticles capable of mediating boron neutron capture therapy and magnetic resonance imaging. The boron manganese tannate nanoparticles can improve the boron intake in tumors and prolong the retention time of boron atoms in the tumors in boron neutron capture therapy, drug distribution is monitored through the nuclear magnetic resonance imaging technology, then the treatment effect of the boron neutron capture therapy is improved, the preparation method is simple, the stability is good, the size is uniform, the boron loading amount is high, and the application prospect is wide. The biological safety is good, and the repeatability is high.

The invention provides a coding gene of coral-derived anticoagulant polypeptide and application, and belongs to the technical field of bioactive peptides. The invention provides an anticoagulant polypeptide GcKuz1. The anticoagulant polypeptide GcKuz1 comprises a mature peptide fragment as shown in SEQ ID No.1. The invention also provides a preparation method of the anticoagulant polypeptide GcKuz1. The polypeptide GcKuz1 is combined with KLKB1 in a thrombin system, so that the anti-thrombus and anti-coagulation effects are achieved, and the polypeptide does not cause hemolysis and cytotoxicity, has no bleeding risk and has good biological safety. The anticoagulant polypeptide disclosed by the invention has the effect of treating thrombotic diseases, such as arterial thrombotic diseases, venous thrombotic diseases and capillary thrombotic diseases.

The invention belongs to the technical field of gene engineering, and provides application of a magnaporthe oryzae Pmk1 protein K347 site as a target for inhibiting the pathogenicity of magnaporthe oryzae. Researches find that after the K347 site of the magnaporthe oryzae Pmk1 protein is mutated, the pathogenicity of magnaporthe oryzae is remarkably reduced, growth and expansion of magnaporthe oryzae hyphae can be inhibited, autophagy in the conidium germination process can be promoted, and secretion of effect protein of magnaporthe oryzae can be inhibited. Compared with the drug design aiming at the whole Pmk1 gene, the drug design aiming at the K347 site disclosed by the invention is accurate in range and has very high specificity and biological safety. The invention provides a new target site for developing a pyricularia grisea antibacterial drug, and the site has good application prospect and value in the aspect of preventing and controlling the rice blast.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant human III-type collagen for promoting angiogenesis as well as a preparation method and application of the recombinant human III-type collagen. The recombinant human III-type collagen for promoting angiogenesis has an amino acid sequence as shown in SEQ ID NO. 1. Nine different sites of the full-length natural III-type collagen are replaced by GFOGER sequences which are from the I-type collagen and are specifically combined with integrin sites, the angiogenesis promoting function of the collagen is enhanced under the condition that the total length of natural full-length amino acid is not changed, and meanwhile, four natural integrin sites with low adhesion rate are also replaced; the recombinant III-type collagen has high adhesive force, so that angiogenesis is further promoted. By means of the transformation mode, the angiogenesis rate is increased by 37% or above, the molecular weight of the translated protein is moderate, and the translated protein is easy to prepare.

The invention provides silk fibroin hydrogel containing divalent bioactive metal ions and a preparation method of the silk fibroin hydrogel, and belongs to the technical field of soft and hard tissue repair and medical dressings. The invention provides a silk fibroin hydrogel preparation method, which comprises: S1, dissolving degummed silk by using a dissolving agent to prepare a silk fibroin stock solution; s2, dialyzing the silk fibroin stock solution in water dissolved with divalent metal salt to obtain a silk fibroin composite solution; s3, carrying out heat preservation treatment on the silk fibroin composite solution, then applying shearing force, and incubating to obtain the silk fibroin hydrogel containing the metal ions. The preparation method of the silk fibroin hydrogel is simple, the pH value does not need to be adjusted in the preparation process, a gelatinizing agent does not need to be added, two cross-linking mechanisms of beta-folding cross-linking of a silk fibroin hydrophobic chain segment are promoted under the action of shearing force by chelating and cross-linking a silk fibroin hydrophilic chain segment through divalent metal ions, so that a silk fibroin aqueous solution is rapidly gelatinized, and the silk fibroin hydrogel is prepared. And meanwhile, one or more divalent metal ions can be compounded according to expected purposes, and good operability, biological safety and multifunctionality are achieved.

The invention relates to an aromatic soluble polymer microneedle as well as a preparation method and application thereof. The preparation method comprises the following steps: adding a zinc acetate hexahydrate aqueous solution and a Tris buffer solution into a eugenol-curcumin mixed ethanol solution to obtain self-assembled carrier-free nanoparticles containing eugenol and curcumin; and dissolving the nano-particles in a soluble hyaluronic acid solution, drying in a microneedle mold, and demolding to obtain the aromatic soluble polymer microneedle. The structure of the aromatic soluble polymer microneedle is that self-assembled carrier-free nanoparticles are wrapped in a soluble hyaluronic acid microneedle. Compared with the prior art, the aromatic soluble polymer microneedle prepared by the invention can overcome skin barrier and quickly absorb moisture and dissolve so as to promote the transdermal absorption effect of active substances; a perfume delivery system is constructed by using the soluble polymer microneedle, so that the biocompatibility is improved, the slow release control capability of the perfume can be effectively enhanced, and a new path is opened up for clinical application of inflammatory diseases.

The invention relates to the technical field of screening and application of probiotics, and particularly provides a novel bacillus coagulans strain and application of the novel bacillus coagulans strain. The bacillus coagulans is screened from naturally fermented soybean paste, has good biological safety, strong stress resistance to gastrointestinal tract environment, high yield of exopolysaccharide and protease, strong bacteriostasis and oxidation resistance, can efficiently degrade cholesterol, is beneficial to maintaining intestinal health, and can be widely applied to the fields of food, health care products and the like.

The invention discloses a grain specific promoter in the early stage of rice filling and application thereof, the promoter is named as proASP1, and the nucleotide sequence of the promoter is shown as SEQ ID NO: 1. The promoter has highly strict spatio-temporal expression specificity, the activation expression of the promoter is only limited in grains in the early stage of rice filling (4-12 days after flowering), especially the expression of genes is efficiently driven in endosperm and aleurone layers, and the expression is not leaked in other tissues such as roots, stems, leaves, leaf sheaths and glumes and grains in the middle and later stages of filling. The invention provides a basic and precious molecular tool for gene function research, quality improvement (such as protein and starch synthesis regulation) and bioreactor development in a key window period of rice grain development, and has important scientific research and application values.

The invention relates to the field of osteoarthritis drug treatment, in particular to application of RuO2 nano-enzyme in preparation of a drug for treating osteoarthritis, and particularly relates to knee osteoarthritis. The RuO2 nano-enzyme disclosed by the invention is prepared according to the following method: carrying out incubation deposition on Cu2O sphere nano-particles and RuCl3 to obtain Cu2O and RuO2, and etching Cu2O and RuO2 spheres to obtain the RuO2 nano-enzyme. The RuO2 nano-enzyme provided by the invention is a hollow RuO2 nano-enzyme sphere, and after the RuO2 nano-enzyme is horizontally used in an animal body for intervention, the hollow RuO2 nano-enzyme sphere can be used as a hollow RuO2 nano-enzyme sphere; the RuO2 nano-enzyme can effectively delay the development of knee osteoarthritis of a mouse knee osteoarthritis model caused by medial meniscus instability (DMM), improve the pain condition and movement function of a DMM modeling mouse, reduce the gonarthromeningitis degree and relieve knee joint cartilage degeneration and injury, and the effectiveness of the RuO2 nano-enzyme in delaying the knee osteoarthritis disease is further proved. The invention provides a novel method for treating knee osteoarthritis, and has strong practicability and application prospect.

The invention provides a nano-drug for targeted diagnosis and treatment of atherosclerotic plaque, the nano-particles are constructed by EGCG, formaldehyde and L-arginine, the antioxidant characteristic of EGCG is retained, and the nano-drug constructed by modifying Mn < 2 + > and DKK1 antibodies on the basis has a good relaxation value and can be used for an atherosclerotic plaque specific MRI imaging enhancer; the Cy5-labeled nano-drug can be used for an atherosclerotic plaque specific in-vivo imaging developer. The nano-drug provided by the invention has good biological safety, can delay plaque development and improve plaque stability, and is a nano-drug for precisely targeting atherosclerotic plaque and treating the atherosclerotic plaque.